CD19 and B-cell chronic lymphocytic leukemia: (55) conducted a phase I/II non-randomized clinical trial (NCT01865617) to evaluate the feasibility, safety, and efficacy of CD19-targeted CAR-T therapy combined with ibrutinib in patients with R/R CLL refractory to ibrutinib monotherapy.